Subtype
Malignant Urinary System Neoplasm
CI-CAN-00001187Explore in graph →
887 active trials28 approved drugs109 evidence items
- NCIt
- C9297
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001187Explore in graph →
Clinical trials
3,851 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (556)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03022825 | QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer | active not recruiting | Phase 2 / Phase 3 | 190 | ImmunityBio, Inc.INDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT01812369 | Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer(VESPER) | completed | Phase 3 | 500 | University Hospital, RouenOTHER | 1 |
| Oct 6, 2025 |
| clinicaltrials |
| NCT01120249 | S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery(S0931) | completed | Phase 3 | 1,545 | SWOG Cancer Research NetworkNETWORK | 2 | Sep 16, 2025 | clinicaltrials |
| NCT03937219 | Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(COSMIC-313) | active not recruiting | Phase 3 | 855 | ExelixisINDUSTRY | 25 | Sep 10, 2025 | clinicaltrials |
| NCT07165418 | A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI | not yet recruiting | Phase 3 | 116 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT04510597 | Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial(PROBE) | recruiting | Phase 3 | 364 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04534075 | Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial(FIDURA) | completed | Phase 3 | 354 | Sahlgrenska University HospitalOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT00930033 | Clinical Trial to Assess the Importance of Nephrectomy(CARMENA) | completed | Phase 3 | 452 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT02684006 | A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) | completed | Phase 3 | 886 | PfizerINDUSTRY | 21 | Jul 30, 2025 | clinicaltrials |
| NCT06537154 | NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment(NEO-BLAST) | recruiting | Phase 2 / Phase 3 | 688 | Peter BlackOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT07067749 | Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer(TEMPO-MIBC) | recruiting | Phase 3 | 92 | University of Rome Tor VergataOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT04574960 | Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)(NAUTICAL) | recruiting | Phase 3 | 14 | University Health Network, TorontoOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06738251 | A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma | recruiting | Phase 3 | 402 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT05796973 | Measuring Oncological Value of Exercise and Statin(MOVES) | recruiting | Phase 3 | 240 | Tampere University HospitalOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT05219318 | Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors(SPICI) | active not recruiting | Phase 3 | 22 | University Hospital, BordeauxOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT03592472 | A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | recruiting | Phase 3 | 413 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 6 | Apr 13, 2025 | clinicaltrials |
| NCT06196736 | A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer | recruiting | Phase 3 | 432 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06493552 | Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors | recruiting | Phase 2 / Phase 3 | 700 | Vasgene Therapeutics, IncINDUSTRY | 1 | Apr 3, 2025 | clinicaltrials |
| NCT00720941 | Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma(COMPARZ) | completed | Phase 3 | 1,110 | Novartis PharmaceuticalsINDUSTRY | 14 | Mar 30, 2025 | clinicaltrials |
| NCT06903260 | Robot-assisted Partial Nephrectomy With and Without Mixed Reality (REALITATEM Study) | completed | Phase 3 | 45 | Hospital Moinhos de VentoOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT02807636 | Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma(IMvigor130) | completed | Phase 3 | 1,213 | Hoffmann-La RocheINDUSTRY | 35 | Feb 24, 2025 | clinicaltrials |
| NCT06364904 | A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma. | not yet recruiting | Phase 3 | 210 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06696794 | Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients | recruiting | Phase 3 | 180 | Shaogang WangOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT03013946 | Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy(PREPARE) | terminated | Phase 3 | 121 | AIO-Studien-gGmbHOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT02951325 | Bladder Cancer Adjuvant Radiotherapy Trial(BART) | active not recruiting | Phase 3 | 153 | Tata Memorial CentreOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06364631 | CARE1 Pragmatic Clinical Trial(CARE1) | recruiting | Phase 3 | 1,250 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 4 | Jan 16, 2025 | clinicaltrials |
| NCT05522231 | Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) | active not recruiting | Phase 2 / Phase 3 | 265 | HutchmedINDUSTRY | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06750419 | 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study | recruiting | Phase 3 | 82 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03138512 | A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney(CheckMate 914) | completed | Phase 3 | 1,641 | Bristol-Myers SquibbINDUSTRY | 25 | Dec 18, 2024 | clinicaltrials |
| NCT03799835 | Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients(ALBAN) | active not recruiting | Phase 3 | 517 | UNICANCEROTHER | 3 | Dec 11, 2024 | clinicaltrials |
| NCT04806178 | Immunological Response of Bladder Cancer Patients Under BCG(IMMUNOBCG) | completed | Phase 3 | 30 | University of Campinas, BrazilOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT01627197 | Adjuvant Intraarterial Chemotherapy Following Surgery to Treat Locally Advanced Bladder Cancer | completed | Phase 3 | 186 | Sun Yat-sen UniversityOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT05600322 | Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer | completed | Phase 3 | 158 | PhotocureINDUSTRY | 1 | Oct 3, 2024 | clinicaltrials |
| NCT05136898 | Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) | completed | Phase 3 | 8 | UroGen Pharma Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06592326 | 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer | recruiting | Phase 3 | 460 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05822934 | Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer | unknown | Phase 3 | 20 | Assiut UniversityOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT02773849 | ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) | completed | Phase 3 | 157 | Ferring PharmaceuticalsINDUSTRY | 1 | Jul 29, 2024 | clinicaltrials |
| NCT04688931 | A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer(ATLAS) | terminated | Phase 3 | 282 | UroGen Pharma Ltd.INDUSTRY | 10 | Jun 6, 2024 | clinicaltrials |
| NCT03849118 | 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study(89ZR-TLX250) | completed | Phase 3 | 300 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 8 | May 17, 2024 | clinicaltrials |
| NCT06301308 | A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial | withdrawn | Phase 3 | 0 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT02928406 | A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract | completed | Phase 3 | 1,004 | Hoffmann-La RocheINDUSTRY | 32 | Apr 4, 2024 | clinicaltrials |
| NCT02145871 | A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy | completed | Phase 3 | 282 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT04197986 | Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations(PROOF302) | terminated | Phase 3 | 39 | QED Therapeutics, a BridgeBio companyINDUSTRY | 11 | Mar 13, 2024 | clinicaltrials |
| NCT05302284 | A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma | recruiting | Phase 3 | 452 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT00606866 | MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma(MRI) | completed | Phase 3 | 57 | University of ChicagoOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT06146777 | Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy | not yet recruiting | Phase 3 | 468 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Nov 29, 2023 | clinicaltrials |
| NCT03216525 | Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol | recruiting | Phase 3 | 136 | Brigham and Women's HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT02426125 | A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer(RANGE) | completed | Phase 3 | 530 | Eli Lilly and CompanyINDUSTRY | 23 | Aug 21, 2023 | clinicaltrials |
| NCT00352079 | BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer | terminated | Phase 3 | 41 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Oct 16, 2025source: clinicaltrials